EICHOR
● Terminated
A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)
Condition: RET-fusion Non Small Cell Lung Cancer · Lung Neoplasm · Carcinoma, Non-Small-Cell Lung · Sponsor: Hoffmann-La Roche
About this study
This is an international, randomized, open-label, Phase 3 study designed to evaluate whether the potent and selective RET inhibitor, pralsetinib, improves outcomes when compared to a platinum chemotherapy-based regimen chosen by the Investigator from a list of standard of care treatments, as measured primarily by progression free survival (PFS), for participants with RET fusion-positive metastatic NSCLC who have not previously received systemic anticancer therapy for metastatic disease.
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (74)
| Hospital Britanico | Buenos Aires, Argentina | — |
| Centro Oncologico Riojano Integral (CORI) | La Rioja, Argentina | — |
| Royal North Shore Hospital | St Leonards, New South Wales, Australia | — |
| UZ Antwerpen | Edegem, Belgium | — |
| Hospital Sao Lucas - PUCRS | Porto Alegre, Rio Grande do Sul, Brazil | — |
| Hospital A. C. Camargo | São Paulo, São Paulo, Brazil | — |
| Clinica CIMCA | San José, Costa Rica | — |
| Institut Bergonie CLCC Bordeaux | Bordeaux, France | — |
| Hôpital Ambroise Paré - Boulogne-Billancourt | Boulogne-Billancourt, France | — |
| Hôpital Louis Pradel, Hospices Civils de Lyon | Bron, France | — |
| CHRU Lille Service de Pneumologie et Oncologie Thoracique | Lille, France | — |
| Institut Paoli Calmettes | Marseille, France | — |
+ 62 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04222972